Prof Geraint Davies BM PhD FRCP DTM&H

Professor of Infection Pharmacology Clinical Infection, Microbiology and Immunology

    Research

    Research Overview

    "My research focuses on improving the treatment of tuberculosis, ranging from evaluation of the value of preclinical models through pharmacokinetic-pharmacodynamic studies and clinical trials to evidence synthesis and policy. "

    Research Group Membership

    Research Grants

    PanACEA Biomarker Extension Project (PANBIOME)

    EDCTP (NETHERLANDS)

    January 2013 - June 2015

    Randomised trial of high-dose rifampin in patients with new, smear-positive TB

    NATIONAL INSTITUTES OF HEALTH (NIH) (USA)

    August 2011 - July 2017

    Model-based preclinical development of anti-tuberculosis drug combinations (preDICT-TB)

    EUROPEAN COMMISSION

    May 2012 - October 2017

    Population pharmacokinetic-pharmacodynamic modelling to optimise treatments for HIV,TB and malaria

    WELLCOME TRUST (UK)

    November 2008 - October 2012

    Modulation of TB-HIV drug interaction by host genetic influences

    MEDICAL RESEARCH COUNCIL (MRC)

    July 2010 - June 2013

    Wellcome Trust Clinical PhD Programme - Derek Sloan: Understanding mycobacterial persistence in sputum during treatment for tuberculosis

    WELLCOME TRUST (UK)

    August 2009 - July 2012

    Investigation into the relationship between pharmacological and immunological responses to tuberculosis treatment and risk of early death

    THE BRITISH INFECTION ASSOCIATION (UK)

    January 2013 - August 2014

    Adjunctive Rifampicin to Reduce Early mortality from Staphylococcus aureus bacteraemia: a multi-centre, randomised, double blind, placebo controlled trial (the ARREST trial).

    DEPARTMENT OF HEALTH (UK) (NIHR)

    October 2012 - June 2016